Glucagon-like peptide-1 (GLP-1) receptor can be an ideal target in the introduction of incretin-based therapies for diabetes and obesity. after an extended incubation; right-shifted the dose-response curve of GLP-128Not reportedCompound A27IC50: 5.94 mol/L (wild type receptor) IC50: 5.10 mol/L (mutant receptor)Increased cAMP productionNot reportedCompound B27IC50: 25 mol/L (wild type receptor) IC50: 20 mol/L (mutant receptor)Increased… Continue reading Glucagon-like peptide-1 (GLP-1) receptor can be an ideal target in the